Developer docs
API playgroundTry for free, no card

Search company profiles

BriaCell Therapeutics

Full company profile

uuid0002933

Namestring
BriaCell Therapeutics
Legal namestring
BriaCell Therapeutics Corp.
Websiteurl
briacell.com
Company typeenum
Public
Founded yearint
2014
Descriptiontext

BriaCell Therapeutics Corp. is a clinical-stage immuno-oncology biotechnology company developing targeted whole-cell cancer immunotherapies. The company's lead asset, Bria-IMT, is an off-the-shelf cell-based immunotherapy with FDA Fast Track designation currently in pivotal Phase 3 evaluation (the Bria-ABC study) for metastatic breast cancer, particularly in patients who have failed antibody-drug conjugate (ADC), checkpoint inhibitor (CPI), and CDK4/6 inhibitor therapies and those with CNS metastases. The second-generation Bria-OTS+ platform is engineered to express 15 unique HLA types across four independent cell lines, enabling personalized off-the-shelf immunotherapy matched to greater than 99% of patients via a simple saliva test.

The pipeline built on the Bria-OTS+ platform includes Bria-BRES+ (Phase 1/2a breast cancer, FDA-cleared), Bria-PROS+ (Phase 1/2a prostate cancer, NCI-funded), Bria-MEL+ (preclinical melanoma), Bria-LUNG+ (lung cancer, trials planned 2027), and Bria-OVA+ (ovarian). Phase 2 results demonstrated 16.6 months median overall survival in heavily pre-treated metastatic breast cancer patients with up to 2-fold improvement versus literature comparators and a 71% intracranial objective response rate in CNS metastases.

BriaCell has no commercialized products and is pre-revenue. The company funds operations through repeated public equity offerings (over $85 million raised across 2024-2026), a $2 million NCI SBIR grant, and a $4 million strategic investment from Prevail Partners. Go-to-market is conducted via enterprise field sales targeting major cancer centers, with 79 clinical trial sites across 23 US states. Distribution is through FDA-regulated clinical supply chains. BriaCell is publicly traded on Nasdaq (BCTX) and TSX (BCT), with corporate offices in Philadelphia, PA and West Vancouver, BC, and a majority-owned subsidiary (BriaPro Therapeutics Corp., ~78% owned) focused on additional cancer immunotherapy programs including Soluble CD80.

Short descriptiontext

BriaCell Therapeutics is a clinical-stage immuno-oncology company developing off-the-shelf whole-cell cancer immunotherapies, with lead candidate Bria-IMT in pivotal Phase 3 for metastatic breast cancer and a Bria-OTS+ platform extending into prostate, lung, melanoma, and ovarian cancers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersPhiladelphia, United States
HQ citystring
Philadelphia
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cancer immunotherapy, cell-based therapy, oncology biopharmaceuticals, targeted immunotherapy, clinical stage biotechnology
Industry4 codes
PRIMARYHLAAAEAB
Therapeutic Vaccines (cancer, chronic infection immunotherapy)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAKAFAJ
Breast Oncology
SECONDARYHLAAANAK
Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies)
SECONDARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Cancer Immunotherapy
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Development
TypeOne Time License
Description

Pre-revenue clinical-stage biotechnology company developing novel immunotherapies for cancer treatment. No commercialized products yet. Revenue will be generated through drug sales upon regulatory approval.

briacell.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 10 records shown
1Bria-IMT
Description

Lead candidate - patented, off-the-shelf, cell-based, targeted immunotherapy for metastatic breast cancer with FDA Fast Track designation

briacell.com
+9 more records
Core offering1 text field

BriaCell Therapeutics is a clinical-stage immuno-oncology biotechnology company developing targeted cell-based immunotherapies for cancer treatment. The company's lead candidate, Bria-IMT, is an off-the-shelf whole-cell immunotherapy in pivotal Phase 3 development for metastatic breast cancer with FDA Fast Track designation. The Bria-OTS+ next-generation platform uses HLA-matching technology to deliver personalized off-the-shelf immunotherapies across multiple cancer types including breast, prostate, lung, melanoma, and ovarian cancers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • Median overall survival of 16.6 months in heavily pre-treated metastatic breast cancer patients (Phase 2 final results)
+6 more records
Product overview1 text field

BriaCell Therapeutics is a clinical-stage immuno-oncology company developing a portfolio of targeted cellular immunotherapies for cancer treatment. The company's lead product is Bria-IMT™, an off-the-shelf cell-based immunotherapy with FDA Fast Track designation in pivotal Phase 3 development for metastatic breast cancer. The Bria-OTS+™ platform serves as the next-generation foundation, enabling personalized off-the-shelf treatments through HLA matching across multiple cancer types including breast (Bria-BRES+™), prostate (Bria-PROS+™), lung (Bria-LUNG+™), melanoma (Bria-MEL+™), and ovarian (Bria-OVA+™) cancers. The company also maintains BriaDx™ as a companion diagnostic for patient selection. BriaCell operates with corporate offices in Philadelphia, PA and West Vancouver, BC, and is listed on Nasdaq (BCTX) and Toronto Stock Exchange (BCT).

Product and service5 records
1Bria-IMT
CategoryCell-based Immunotherapy
Description

Patented, off-the-shelf, cell-based targeted immunotherapy that activates the patient's immune system to specifically kill cancer cells. FDA Fast Track designated lead candidate in pivotal Phase 3 study for metastatic breast cancer, with demonstrated activity in CPI and ADC resistant patients and patients with CNS metastases.

2Bria-OTS+/Bria-OTS+
CategoryImmunotherapy Platform
Description

Next-generation personalized off-the-shelf cell-based immunotherapy platform engineered to express multiple immune-activating cytokines and co-stimulatory molecules. Designed to express 15 unique HLA types in 4 independent cell lines to provide matched treatment to greater than 99% of patients through a simple saliva test.

3Bria-PROS+
CategoryCell-based Immunotherapy
Description

Next-generation personalized off-the-shelf immunotherapy candidate for prostate cancer. Activates adaptive and innate immunity including T-cells, dendritic cells, and natural killer cells.

4Bria-BRES+
CategoryCell-based Immunotherapy
Description

Next-generation personalized off-the-shelf immunotherapy candidate for breast cancer within the Bria-OTS+ platform with enhanced immune engagement features. FDA cleared for Phase 1/2a clinical study.

5Bria-LUNG+
Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierStrategicTypeTechnology or IntegrationAnnounced on2026-06-25
Description

Netherlands-based microneedle drug-delivery company. Memorandum of Understanding to support commercial readiness of BriaCell's Bria-IMT using Uneedle's proprietary intradermal microneedle technology. Technology currently being used in Phase 3 study for faster, more convenient administration.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-11-20
Description

Collaboration uses Receptor.AI's platform to design highly selective anti-cancer kinase inhibitor products for BriaPro subsidiary.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2025-10-21
Description

Collaboration to support development of Bria-OTS+ platform including Phase 1 clinical trial for breast cancer. Partnership leverages MSK's clinical and manufacturing expertise to accelerate immunotherapy development.

4MSK Accelerator 2025
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2025-08-13
Description

BriaCell selected for MSK's 2025 Therapeutics Accelerator Program for Bria-OTS+ for Cancer. Provides manufacturing, IND, and clinical protocol support.

thefly.com
Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2023-05-15
Description

Prevail InfoWorks acts as Contract Research Organization providing clinical services and real-time data analytics to support BriaCell's pivotal study in advanced metastatic breast cancer.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2016-12-05
Description

Research agreement with Terasaki Foundation Laboratory for scientific collaboration.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

ThinkEquity serves as sole placement agent for multiple public offerings including the $8.5 million (September 2024), $5.0 million (May 2024), $13.8 million (April 2025), $15 million (July 2025), $30 million (January 2026), and $4.7 million (June 2026) offerings.

Strategic tierStrategicTypeTechnology or Integration
Description

Clinical supply agreement for Bria-OTS study evaluating Bria-OTS in combination with anti-PD-1 antibody tislelizumab in advanced cancers.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Cell therapy biotech developing SPEAR T-cell receptor therapies for solid tumors including synovial sarcoma. Comparable as a clinical-stage cell therapy company targeting solid tumor indications with similar late-stage clinical and regulatory pathway.

TypeEmerging player
Description

Clinical-stage oncology biotech developing antibody-based therapeutics including ADCs and bispecifics. Comparable as a clinical-stage oncology company developing novel biologics for metastatic breast cancer and other solid tumors with similar late-stage development profile.

TypeBroad incumbent
Description

Large oncology immunotherapy company with individualized neoantigen cancer vaccine programs (BNT122/iNeST) and a broad mRNA-based oncology pipeline. Comparable in pursuing personalized cancer immunotherapy approaches with HLA/neoantigen targeting, though with much larger scale and COVID-vaccine cash flows.

TypeBroad incumbent
Description

Large biotech with extensive oncology mRNA vaccine pipeline including personalized neoantigen programs (mRNA-4157/V940 with Merck). Comparable in pursuing personalized cancer vaccine approaches but operating at much greater scale with COVID vaccine cash flows.

TypeEmerging player
Description

Clinical-stage Korean biotech developing immuno-oncology and cell therapy products including GX-188E therapeutic HPV vaccine. Comparable as a clinical-stage immuno-oncology company with cell therapy and vaccine programs targeting cancer, with similar pipeline breadth and stage of development.

6Innate Pharma
TypeEmerging player
Description

Clinical-stage immuno-oncology company developing antibody-based therapeutics engaging innate immune cells. Comparable as a clinical-stage oncology immunotherapy company with similar development stage, partnership-driven model (including with AstraZeneca and Sanofi), and small-mid cap profile.

TypeEmerging player
Description

Clinical-stage immuno-oncology company developing antibody-based therapeutics targeting novel immune checkpoints. Comparable as a clinical-stage oncology biotech pursuing novel immunotherapy approaches with similar small-cap profile and partnership-heavy business model.

TypeDirect peer
Description

Clinical-stage cell therapy biotech with FDA-approved tumor-infiltrating lymphocyte (lifileucel) therapy for solid tumors. Directly comparable as a clinical-stage cell-based immunotherapy company pursuing regulatory approval in oncology with similar manufacturing complexity and pre-commercial profile.

TypeDirect peer
Description

Clinical-stage biotech developing personalized neoantigen cancer vaccines (GRANITE platform) for solid tumors. Directly comparable as a personalized cancer immunotherapy developer with similar HLA/neoantigen matching approach and clinical-stage profile in oncology.

TypeDirect peer
Description

Allogeneic CAR-T cell therapy developer with multiple clinical programs in hematologic and solid tumors. Directly comparable as an off-the-shelf cell therapy platform targeting cancer, with similar allogeneic manufacturing and HLA-related considerations.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers10 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds12 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BriaCell Therapeutics

Cancer Immunotherapybriacell.com

BriaCell Therapeutics is a clinical-stage immuno-oncology company developing off-the-shelf whole-cell cancer immunotherapies, with lead candidate Bria-IMT in pivotal Phase 3 for metastatic breast cancer and a Bria-OTS+ platform extending into prostate, lung, melanoma, and ovarian cancers.

What BriaCell Therapeutics does

BriaCell Therapeutics Corp. is a clinical-stage immuno-oncology biotechnology company developing targeted whole-cell cancer immunotherapies. The company's lead asset, Bria-IMT, is an off-the-shelf cell-based immunotherapy with FDA Fast Track designation currently in pivotal Phase 3 evaluation (the Bria-ABC study) for metastatic breast cancer, particularly in patients who have failed antibody-drug conjugate (ADC), checkpoint inhibitor (CPI), and CDK4/6 inhibitor therapies and those with CNS metastases. The second-generation Bria-OTS+ platform is engineered to express 15 unique HLA types across four independent cell lines, enabling personalized off-the-shelf immunotherapy matched to greater than 99% of patients via a simple saliva test.

The pipeline built on the Bria-OTS+ platform includes Bria-BRES+ (Phase 1/2a breast cancer, FDA-cleared), Bria-PROS+ (Phase 1/2a prostate cancer, NCI-funded), Bria-MEL+ (preclinical melanoma), Bria-LUNG+ (lung cancer, trials planned 2027), and Bria-OVA+ (ovarian). Phase 2 results demonstrated 16.6 months median overall survival in heavily pre-treated metastatic breast cancer patients with up to 2-fold improvement versus literature comparators and a 71% intracranial objective response rate in CNS metastases.

BriaCell has no commercialized products and is pre-revenue. The company funds operations through repeated public equity offerings (over $85 million raised across 2024-2026), a $2 million NCI SBIR grant, and a $4 million strategic investment from Prevail Partners. Go-to-market is conducted via enterprise field sales targeting major cancer centers, with 79 clinical trial sites across 23 US states. Distribution is through FDA-regulated clinical supply chains. BriaCell is publicly traded on Nasdaq (BCTX) and TSX (BCT), with corporate offices in Philadelphia, PA and West Vancouver, BC, and a majority-owned subsidiary (BriaPro Therapeutics Corp., ~78% owned) focused on additional cancer immunotherapy programs including Soluble CD80.

BriaCell Therapeutics firmographics

Firmographics
Name
BriaCell Therapeutics
Legal name
BriaCell Therapeutics Corp.
Website
https://briacell.com
Company type
Public
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Short description
BriaCell Therapeutics is a clinical-stage immuno-oncology company developing off-the-shelf whole-cell cancer immunotherapies, with lead candidate Bria-IMT in pivotal Phase 3 for metastatic breast cancer and a Bria-OTS+ platform extending into prostate, lung, melanoma, and ovarian cancers.
Ownership category
akta.pro rank

BriaCell Therapeutics industry classification

Industry
Product category
Cancer Immunotherapy
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAEAB
Therapeutic Vaccines (cancer, chronic infection immunotherapy)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAKAFAJ
Breast Oncology
SECONDARYHLAAANAK
Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies)
SECONDARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Cancer immunotherapy
  • Cell-based therapy
  • Oncology biopharmaceuticals
  • Targeted immunotherapy
  • Clinical stage biotechnology

Where BriaCell Therapeutics is headquartered

Location

Headquarters

HQ city
Philadelphia
HQ country
United States
HQ region
North America

Offices2 records

Markets served

BriaCell Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Development: Pre-revenue clinical-stage biotechnology company developing novel immunotherapies for cancer treatment. No commercialized products yet. Revenue will be generated through drug sales upon regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels8 records

BriaCell Therapeutics product offering

Product offering

Core offering

BriaCell Therapeutics is a clinical-stage immuno-oncology biotechnology company developing targeted cell-based immunotherapies for cancer treatment. The company's lead candidate, Bria-IMT, is an off-the-shelf whole-cell immunotherapy in pivotal Phase 3 development for metastatic breast cancer with FDA Fast Track designation. The Bria-OTS+ next-generation platform uses HLA-matching technology to deliver personalized off-the-shelf immunotherapies across multiple cancer types including breast, prostate, lung, melanoma, and ovarian cancers.

Product overview

BriaCell Therapeutics is a clinical-stage immuno-oncology company developing a portfolio of targeted cellular immunotherapies for cancer treatment. The company's lead product is Bria-IMT™, an off-the-shelf cell-based immunotherapy with FDA Fast Track designation in pivotal Phase 3 development for metastatic breast cancer. The Bria-OTS+™ platform serves as the next-generation foundation, enabling personalized off-the-shelf treatments through HLA matching across multiple cancer types including breast (Bria-BRES+™), prostate (Bria-PROS+™), lung (Bria-LUNG+™), melanoma (Bria-MEL+™), and ovarian (Bria-OVA+™) cancers. The company also maintains BriaDx™ as a companion diagnostic for patient selection. BriaCell operates with corporate offices in Philadelphia, PA and West Vancouver, BC, and is listed on Nasdaq (BCTX) and Toronto Stock Exchange (BCT).

Differentiator

Problem solved

Functional benefit

Brands

  • Bria-IMT: Lead candidate - patented, off-the-shelf, cell-based, targeted immunotherapy for metastatic breast cancer with FDA Fast Track designation
  • Bria-OTS
  • Bria-OTS+
  • Bria-MEL+
  • Bria-LUNG+
  • Bria-PROS+
  • Bria-BRES+
  • Bria-OVA+
  • BriaVax
  • BriaDx

Products and services

  • Bria-IMT Patented, off-the-shelf, cell-based targeted immunotherapy that activates the patient's immune system to specifically kill cancer cells. FDA Fast Track designated lead candidate in pivotal Phase 3 study for metastatic breast cancer, with demonstrated activity in CPI and ADC resistant patients and patients with CNS metastases.
  • Bria-OTS+/Bria-OTS+ Next-generation personalized off-the-shelf cell-based immunotherapy platform engineered to express multiple immune-activating cytokines and co-stimulatory molecules. Designed to express 15 unique HLA types in 4 independent cell lines to provide matched treatment to greater than 99% of patients through a simple saliva test.
  • Bria-PROS+ Next-generation personalized off-the-shelf immunotherapy candidate for prostate cancer. Activates adaptive and innate immunity including T-cells, dendritic cells, and natural killer cells.
  • Bria-BRES+ Next-generation personalized off-the-shelf immunotherapy candidate for breast cancer within the Bria-OTS+ platform with enhanced immune engagement features. FDA cleared for Phase 1/2a clinical study.
  • Bria-LUNG+

Quantifiable outcome

  • Median overall survival of 16.6 months in heavily pre-treated metastatic breast cancer patients (Phase 2 final results)
  • +6 more outcomes

Companies that use BriaCell Therapeutics

Customer profile

Named customers10 records

Segments4 records

Ideal customer profiles2 records

BriaCell Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

BriaCell Therapeutics partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered strategic, minor and core.

  • UneedlestrategicTechnology or Integration · 25 June 2026Netherlands-based microneedle drug-delivery company. Memorandum of Understanding to support commercial readiness of BriaCell's Bria-IMT using Uneedle's proprietary intradermal microneedle technology. Technology currently being used in Phase 3 study for faster, more convenient administration.
  • Receptor.AIminorStrategic or Co-development Partner · 20 November 2025Collaboration uses Receptor.AI's platform to design highly selective anti-cancer kinase inhibitor products for BriaPro subsidiary.
  • Memorial Sloan Kettering Cancer Center's Therapeutics AcceleratorstrategicStrategic or Co-development Partner · 21 October 2025Collaboration to support development of Bria-OTS+ platform including Phase 1 clinical trial for breast cancer. Partnership leverages MSK's clinical and manufacturing expertise to accelerate immunotherapy development.
  • MSK Accelerator 2025strategicStrategic or Co-development Partner · 13 August 2025BriaCell selected for MSK's 2025 Therapeutics Accelerator Program for Bria-OTS+ for Cancer. Provides manufacturing, IND, and clinical protocol support.
  • Prevail InfoWorks, LLCcoreImplementation/ SI/ Consulting Partner · 15 May 2023Prevail InfoWorks acts as Contract Research Organization providing clinical services and real-time data analytics to support BriaCell's pivotal study in advanced metastatic breast cancer.
  • Terasaki Foundation LaboratoryminorStrategic or Co-development Partner · 5 December 2016Research agreement with Terasaki Foundation Laboratory for scientific collaboration.
  • ThinkEquitycoreChannel Partner/ Reseller/ DistributorThinkEquity serves as sole placement agent for multiple public offerings including the $8.5 million (September 2024), $5.0 million (May 2024), $13.8 million (April 2025), $15 million (July 2025), $30 million (January 2026), and $4.7 million (June 2026) offerings.
  • BeiGenestrategicTechnology or IntegrationClinical supply agreement for Bria-OTS study evaluating Bria-OTS in combination with anti-PD-1 antibody tislelizumab in advanced cancers.

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

BriaCell Therapeutics competitors and assessment

Company assessment

Direct peers

  • Adaptimmune Therapeutics: Cell therapy biotech developing SPEAR T-cell receptor therapies for solid tumors including synovial sarcoma. Comparable as a clinical-stage cell therapy company targeting solid tumor indications with similar late-stage clinical and regulatory pathway.
  • Iovance Biotherapeutics: Clinical-stage cell therapy biotech with FDA-approved tumor-infiltrating lymphocyte (lifileucel) therapy for solid tumors. Directly comparable as a clinical-stage cell-based immunotherapy company pursuing regulatory approval in oncology with similar manufacturing complexity and pre-commercial profile.
  • Gritstone bio: Clinical-stage biotech developing personalized neoantigen cancer vaccines (GRANITE platform) for solid tumors. Directly comparable as a personalized cancer immunotherapy developer with similar HLA/neoantigen matching approach and clinical-stage profile in oncology.
  • Allogene Therapeutics: Allogeneic CAR-T cell therapy developer with multiple clinical programs in hematologic and solid tumors. Directly comparable as an off-the-shelf cell therapy platform targeting cancer, with similar allogeneic manufacturing and HLA-related considerations.

Emerging players

  • MacroGenics: Clinical-stage oncology biotech developing antibody-based therapeutics including ADCs and bispecifics. Comparable as a clinical-stage oncology company developing novel biologics for metastatic breast cancer and other solid tumors with similar late-stage development profile.
  • Genexine: Clinical-stage Korean biotech developing immuno-oncology and cell therapy products including GX-188E therapeutic HPV vaccine. Comparable as a clinical-stage immuno-oncology company with cell therapy and vaccine programs targeting cancer, with similar pipeline breadth and stage of development.
  • Innate Pharma: Clinical-stage immuno-oncology company developing antibody-based therapeutics engaging innate immune cells. Comparable as a clinical-stage oncology immunotherapy company with similar development stage, partnership-driven model (including with AstraZeneca and Sanofi), and small-mid cap profile.
  • Compugen: Clinical-stage immuno-oncology company developing antibody-based therapeutics targeting novel immune checkpoints. Comparable as a clinical-stage oncology biotech pursuing novel immunotherapy approaches with similar small-cap profile and partnership-heavy business model.

Broad incumbents

  • BioNTech: Large oncology immunotherapy company with individualized neoantigen cancer vaccine programs (BNT122/iNeST) and a broad mRNA-based oncology pipeline. Comparable in pursuing personalized cancer immunotherapy approaches with HLA/neoantigen targeting, though with much larger scale and COVID-vaccine cash flows.
  • Moderna: Large biotech with extensive oncology mRNA vaccine pipeline including personalized neoantigen programs (mRNA-4157/V940 with Merck). Comparable in pursuing personalized cancer vaccine approaches but operating at much greater scale with COVID vaccine cash flows.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

BriaCell Therapeutics social profiles

Digital presence

BriaCell Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BriaCell Therapeutics leadership team

Management profile

Number of profiles

Profiles5 records

BriaCell Therapeutics subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

BriaCell Therapeutics funding detail

Funding detail

Funding overview

Funding rounds12 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BriaCell Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BriaCell Therapeutics

What does BriaCell Therapeutics do?

BriaCell Therapeutics is a clinical-stage immuno-oncology biotechnology company developing targeted cell-based immunotherapies for cancer treatment. The company's lead candidate, Bria-IMT, is an off-the-shelf whole-cell immunotherapy in pivotal Phase 3 development for metastatic breast cancer with FDA Fast Track designation. The Bria-OTS+ next-generation platform uses HLA-matching technology to deliver personalized off-the-shelf immunotherapies across multiple cancer types including breast, prostate, lung, melanoma, and ovarian cancers.

Is BriaCell Therapeutics a public or private company?

BriaCell Therapeutics is a public company. It is classified as public and is currently operating.

When was BriaCell Therapeutics founded?

BriaCell Therapeutics was founded in 2014. It employs 11 to 50 people.

Where is BriaCell Therapeutics based?

BriaCell Therapeutics is headquartered in Philadelphia, United States, in the North America region.

How does BriaCell Therapeutics make money?

One revenue line is on record: pharmaceutical Development.

Who are BriaCell Therapeutics's main competitors?

Direct peers on record are Adaptimmune Therapeutics, Iovance Biotherapeutics, Gritstone bio and Allogene Therapeutics. Emerging players are MacroGenics, Genexine, Innate Pharma and Compugen. Broad incumbents are BioNTech and Moderna.

Does BriaCell Therapeutics have an API?

No public API is recorded for BriaCell Therapeutics.

What industry is BriaCell Therapeutics in?

BriaCell Therapeutics's product category is Cancer Immunotherapy. Its primary akta.pro industry code is HLAAAEAB, Therapeutic Vaccines (cancer, chronic infection immunotherapy), with a secondary code of HLAKAFAJ, Breast Oncology. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Defense WorldBriacell Therap (NASDAQ:BCTX) Shares Break Above 200 Day Moving Average – Should You Sell?Briacell Therap shares broke above their 200-day moving average on Friday, trading at $3.95. Weiss Ratings reiterated a sell rating, and the stock has an average rating of Sell. The company reported a quarterly loss of $1.50 per share.American Banking and Market NewsBriacell Therap (NASDAQ:BCTX) Stock Crosses Above 200-Day Moving Average – What’s Next?Briacell Therap shares crossed above its 200-day moving average on Friday, trading at $3.95 against a 200-day average of $3.79. Weiss Ratings reissued a sell rating, and the company reported a $1.50 loss per share for the quarter. The stock has a consensus sell rating and a market cap of $34.48 million.Pulse 2.0BriaCell Therapeutics: Interview With CEO Dr. William Williams About Cancer Immunotherapy And Off-The-Shelf Cancer VaccinesBriaCell Therapeutics CEO Dr. William Williams discussed the company's off-the-shelf cancer immunotherapy platform, with lead candidate Bria-IMT in a pivotal Phase 3 trial for metastatic breast cancer. The therapy, derived from a genetically engineered breast cancer cell line, has approximately doubled overall survival in Phase 2 trials. The company plans to advance the trial toward interim efficacy analysis and expand into other solid tumor types.The future of tradingBriaCell Analysis Links Circulating Immune Biomarker to Survival in Metastatic Breast CancerBriaCell Therapeutics presented findings at ESMO 2026 linking circulating immune cells' PD-L1 expression to survival in metastatic breast cancer. The pooled analysis of 111 previously treated patients showed measurements at roughly three months associated with progression-free and overall survival, while pretreatment measurements did not. The findings support further evaluation of CAML PD-L1 to identify patients likely to benefit from immunotherapy.Business & FinancialBriacell Therapeutics Corp.BriaCell Therapeutics presented clinical biomarker findings from a prospective pooled analysis of metastatic breast cancer patients treated with immune-based therapies, including its BriaCell regimen, at the ESMO 2026 congress in Madrid. The company's shares traded unchanged at $4.84.Ticker ReportBriacell Therap (NASDAQ:BCTX) Shares Down 0.5% – Time to Sell?Briacell Therap shares fell 0.5% on Wednesday, trading as low as $3.91. Weiss Ratings reiterated a sell rating, and the stock has a consensus sell rating. The company develops immunotherapies for breast cancer.American Banking and Market NewsBriacell Therap (NASDAQ:BCTX) Shares Down 0.5% – Here’s What HappenedBriacell Therap shares fell 0.5% on Wednesday, trading as low as $3.91 with volume down 42% from average. Weiss Ratings reissued a sell rating, and the company holds an average analyst rating of Sell. The clinical-stage biotech develops immunotherapies for breast cancer.Digital JournalQ&A: Advancing cancer biotech therapies with a multipronged approachBriaCell Therapeutics CEO William V. Williams discussed the company's off-the-shelf cellular immunotherapies, including Bria-IMT in a Phase 3 breast cancer trial and FDA clearance for Bria-PROS+ in prostate cancer. The company also highlighted Bria-MEL+ for melanoma and plans for lung cancer candidates, aiming to deliver precision medicine without the delays of personalized cell therapy.InvestorshangoutCheck out this briacell studyhttps://creatvbio.com/s/Muthuraj-AACR-2026_Abstract-1025.pdf *briacell - CYDY CytoDyn IncA study presented at ESMO 2026 found that circulating cancer-associated macrophage-like cell PD-L1 expression predicts clinical outcomes in metastatic breast cancer treated with immune checkpoint inhibitors. Tissue CPS scores were statistically insignificant, while PD-L1 positive circulating cells at any timepoint improved progression-free survival (HR=0.52, p=0.0201). The findings suggest dynamic blood monitoring may replace static tissue biopsies for regulatory decisions.Ticker ReportHead to Head Analysis: Briacell Therap (NASDAQ:BCTX) & Aligos Therapeutics (NASDAQ:ALGS)Aligos Therapeutics beats Briacell Therap on 11 of 14 factors, including analyst ratings, institutional ownership, and valuation. Aligos has a consensus target price of $38.50, implying 519.97% upside, while Briacell's rating score is 1.00. Aligos also shows higher revenue and lower price-to-earnings ratio.